October 7, 2025
BIOINVEST NEWS: Viking (VKTX)
VikingTherapeutics (VKTX) – BIOINVEST BREAKING NEWS – OBESITY MARKET NEWS – Two major independent events in obesity drug development occurred yesterday with opposite effects on two of our MTSL Recommendations: SKYE (2) and VKTX (32)
VKTX – MTSR/PFE PROXY SHOWS MORE POTENTIAL BUYERS AROUND INCLUDING PFIZER
On a positive note, MTSR’s preliminary merger proxy statement released today and stated there were up to seven interested parties and three companies with bids offered, including PFE. Pfizer agreed to pay $47.50/share upfront and up to $22.50/share in contingent value rights (CVRs) related to MTSR’s monthly GLP-1 (MET-097i) and amylin (MET-233i) plus GLP-1 combination. The proxy is further evidence of the increased demand for obesity assets – and that the process was highly competitive. We previously wrote that we expected that once released the proxy would show several other major players who missed out on MTSR and believe it to be a very positive sign for the blockbuster sector and the evolving obesity M&A outlook. One specific comment was that PFE may explore alternative acquisition candidates in the same therapeutic area as MTSR, based on discussions with PFE representatives, during late-stage negotiations. Hence, the $5 billion+ number was a rounding error for PFE and there are a lot of additional large, well-capitalized Big Pharma/Bios still in the active hunt. That is bullish for our VKTX — and we do expect the Company to be swallowed up eventually at a much higher valuation.